Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Infection01:20

Infection

When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric Humeral Tuberosity Fractures: Presentation, Management, and Early Outcomes.

Journal of the Pediatric Orthopaedic Society of North America·2026
Same author

Epidemiology of early-onset and late-onset invasive infections in Australian neonates and infants: a retrospective multicentre study.

BMJ public health·2025
Same author

Nerve Recovery in Pediatric Supracondylar Humeral Fractures: Assessing the Impact of Time to Surgery.

The Journal of bone and joint surgery. American volume·2025
Same author

Risk Model-Guided Clinical Decision Support for Suicide Screening: A Randomized Clinical Trial.

JAMA network open·2025
Same author

Systemic complications of Aicardi Goutières syndrome using real-world data.

Molecular genetics and metabolism·2024
Same author

Diagnostic Criteria for Primary Tic Disorders: Time for Reappraisal.

Movement disorders : official journal of the Movement Disorder Society·2024
Same journal

Peptidomics in the Spotlight: Advanced Sample Treatment Techniques and Analytical Insights.

Advances in experimental medicine and biology·2026
Same journal

Methods for the Investigation of Protein-Ligands Interactions.

Advances in experimental medicine and biology·2026
Same journal

Sample Preparation Strategies for Microbial Cell Surface Proteomics: Integrating Shaving and Shotgun Approaches.

Advances in experimental medicine and biology·2026
Same journal

Proteomic Sample Preparation for the Petroleum Industry: A Biocorrosion Case Study.

Advances in experimental medicine and biology·2026
Same journal

Proteomic and Functional Comparison of Extracellular Vesicles from Wild-Type and Lyn-Deficient Stromal Cells.

Advances in experimental medicine and biology·2026
Same journal

Proteomic Analysis of Histone Sequence Variants and Post-translationally Modified Forms.

Advances in experimental medicine and biology·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Infectious risks associated with biologics.

David Isaacs1

  • 1Department of Infectious Disease and Microbiology, Children's Hospital at Westmead, Westmead, Australia. davidi@chw.edu.au

Advances in Experimental Medicine and Biology
|May 10, 2013
PubMed
Summary
This summary is machine-generated.

Biologics, used in rheumatology, carry infection and malignancy risks. Pediatric use requires careful risk assessment due to unknown safety profiles in children.

More Related Videos

Recombinant Retroviral Production and Infection of B Cells
09:19

Recombinant Retroviral Production and Infection of B Cells

Published on: February 18, 2011

Related Experiment Videos

Last Updated: May 11, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Recombinant Retroviral Production and Infection of B Cells
09:19

Recombinant Retroviral Production and Infection of B Cells

Published on: February 18, 2011

Area of Science:

  • Immunology
  • Pharmacology
  • Pediatrics

Background:

  • Biologics, including monoclonal antibodies and fusion proteins, target specific cells or cytokines.
  • While established in adult rheumatology, their use is expanding into pediatric care.
  • Significant safety and cost concerns accompany biologic therapy.

Purpose of the Study:

  • To review the safety concerns associated with biologic use, particularly in pediatric populations.
  • To highlight the increased risks of infection and malignancy.
  • To discuss risk mitigation strategies and the need for further research in children.

Main Methods:

  • Literature review of biologics, focusing on safety data.
  • Analysis of infection risks associated with specific biologic classes (e.g., TNF antagonists, B-cell antagonists).
  • Examination of current risk management strategies and knowledge gaps in pediatric use.

Main Results:

  • Tumor Necrosis Factor (TNF) antagonists increase risks of intracellular infections (mycobacteria, fungi, Pneumocystis).
  • B-cell antagonists like rituximab are linked to progressive multifocal leukoencephalopathy.
  • Complement pathway antagonists (eculizumab) are associated with meningococcal infections.

Conclusions:

  • Risk mitigation includes screening for tuberculosis, prophylaxis, and vaccinations.
  • The specific risks of biologics in children remain largely unknown and require dedicated study.
  • Initiating biologics in children necessitates thorough risk-benefit evaluation and informed consent.